Difference between revisions of "Epithelioid sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/abs/10.1200/" to "https://doi.org/10.1200/") |
|||
| Line 29: | Line 29: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 Gounder et al. 2017 (EZH-202)] |
|NR in abstract | |NR in abstract | ||
| style="background-color:#91cf61" |Phase II (RT) | | style="background-color:#91cf61" |Phase II (RT) | ||
| Line 41: | Line 41: | ||
===References=== | ===References=== | ||
| − | # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https:// | + | # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 link to abstract] [https://clinicaltrials.gov/ct2/show/NCT02601950 CT.gov] |
[[Category:Epithelioid sarcoma regimens]] | [[Category:Epithelioid sarcoma regimens]] | ||
Revision as of 15:46, 9 March 2020
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN  ejdavis25
|
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tazemetostat monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Gounder et al. 2017 (EZH-202) | NR in abstract | Phase II (RT) |
Note: this study has not yet been published, to our knowledge.
Chemotherapy
- Tazemetostat (Tazverik) 800 mg PO twice per day
Continued indefinitely
References
- Abstract: Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. link to abstract CT.gov